Cargando…
The Nephrotoxicity of Drugs Used in Causal Oncological Therapies
In recent years, a dynamic development of oncology has been observed, resulting from the increasingly frequent occurrence of neoplasms and therefore, increasing population of patients. The most effective form of therapy for cancer patients is complex multidisciplinary specialized disease management,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776938/ https://www.ncbi.nlm.nih.gov/pubmed/36547174 http://dx.doi.org/10.3390/curroncol29120760 |
_version_ | 1784855981780369408 |
---|---|
author | Hałka, Janusz Spaleniak, Sebastian Kade, Grzegorz Antosiewicz, Stefan Sigorski, Dawid |
author_facet | Hałka, Janusz Spaleniak, Sebastian Kade, Grzegorz Antosiewicz, Stefan Sigorski, Dawid |
author_sort | Hałka, Janusz |
collection | PubMed |
description | In recent years, a dynamic development of oncology has been observed, resulting from the increasingly frequent occurrence of neoplasms and therefore, increasing population of patients. The most effective form of therapy for cancer patients is complex multidisciplinary specialized disease management, including nephro-oncology care. Different forms of renal function impairment are frequently diagnosed in cancer patients. They are caused by different co-morbidities existing before starting the oncologic treatment as well as the direct undesirable effects of this therapy which may cause temporary or irreversible damage of the urinary system—especially kidneys. According to different therapeutic programs, in such cases the degree of renal damage is often crucial for the possibility of further anti-cancer treatment. Medical personnel responsible for delivering care to oncology patients should be properly educated on current methods of prevention and treatment of renal complications resulting from anti-cancer therapy. The development of oncologic medicines design, including especially immuno-oncological agents, obliges us to learn new patomechanisms determining potential adverse effects, including renal complications. This publication is focused on the most important undesirable nephrotoxic effects of the frequently used anti-cancer drugs. |
format | Online Article Text |
id | pubmed-9776938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97769382022-12-23 The Nephrotoxicity of Drugs Used in Causal Oncological Therapies Hałka, Janusz Spaleniak, Sebastian Kade, Grzegorz Antosiewicz, Stefan Sigorski, Dawid Curr Oncol Review In recent years, a dynamic development of oncology has been observed, resulting from the increasingly frequent occurrence of neoplasms and therefore, increasing population of patients. The most effective form of therapy for cancer patients is complex multidisciplinary specialized disease management, including nephro-oncology care. Different forms of renal function impairment are frequently diagnosed in cancer patients. They are caused by different co-morbidities existing before starting the oncologic treatment as well as the direct undesirable effects of this therapy which may cause temporary or irreversible damage of the urinary system—especially kidneys. According to different therapeutic programs, in such cases the degree of renal damage is often crucial for the possibility of further anti-cancer treatment. Medical personnel responsible for delivering care to oncology patients should be properly educated on current methods of prevention and treatment of renal complications resulting from anti-cancer therapy. The development of oncologic medicines design, including especially immuno-oncological agents, obliges us to learn new patomechanisms determining potential adverse effects, including renal complications. This publication is focused on the most important undesirable nephrotoxic effects of the frequently used anti-cancer drugs. MDPI 2022-12-08 /pmc/articles/PMC9776938/ /pubmed/36547174 http://dx.doi.org/10.3390/curroncol29120760 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hałka, Janusz Spaleniak, Sebastian Kade, Grzegorz Antosiewicz, Stefan Sigorski, Dawid The Nephrotoxicity of Drugs Used in Causal Oncological Therapies |
title | The Nephrotoxicity of Drugs Used in Causal Oncological Therapies |
title_full | The Nephrotoxicity of Drugs Used in Causal Oncological Therapies |
title_fullStr | The Nephrotoxicity of Drugs Used in Causal Oncological Therapies |
title_full_unstemmed | The Nephrotoxicity of Drugs Used in Causal Oncological Therapies |
title_short | The Nephrotoxicity of Drugs Used in Causal Oncological Therapies |
title_sort | nephrotoxicity of drugs used in causal oncological therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776938/ https://www.ncbi.nlm.nih.gov/pubmed/36547174 http://dx.doi.org/10.3390/curroncol29120760 |
work_keys_str_mv | AT hałkajanusz thenephrotoxicityofdrugsusedincausaloncologicaltherapies AT spaleniaksebastian thenephrotoxicityofdrugsusedincausaloncologicaltherapies AT kadegrzegorz thenephrotoxicityofdrugsusedincausaloncologicaltherapies AT antosiewiczstefan thenephrotoxicityofdrugsusedincausaloncologicaltherapies AT sigorskidawid thenephrotoxicityofdrugsusedincausaloncologicaltherapies AT hałkajanusz nephrotoxicityofdrugsusedincausaloncologicaltherapies AT spaleniaksebastian nephrotoxicityofdrugsusedincausaloncologicaltherapies AT kadegrzegorz nephrotoxicityofdrugsusedincausaloncologicaltherapies AT antosiewiczstefan nephrotoxicityofdrugsusedincausaloncologicaltherapies AT sigorskidawid nephrotoxicityofdrugsusedincausaloncologicaltherapies |